Skip to main content

Upfront bevacizumab with temozolomide or with temozolomide and irinotecan for unresectable or multifocal glioblastoma.

Publication ,  Journal Article
Lou, E; Reardon, DA; Peters, K; Desjardins, A; Herndon, JE; Coan, AD; Turner, SG; Sumrall, AL; Bailey, L; Friedman, HS; Vredenburgh, JJ
Published in: Journal of Clinical Oncology
May 20, 2011

Duke Scholars

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2011

Volume

29

Issue

15_suppl

Start / End Page

2055 / 2055

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Lou, E., Reardon, D. A., Peters, K., Desjardins, A., Herndon, J. E., Coan, A. D., … Vredenburgh, J. J. (2011). Upfront bevacizumab with temozolomide or with temozolomide and irinotecan for unresectable or multifocal glioblastoma. Journal of Clinical Oncology, 29(15_suppl), 2055–2055. https://doi.org/10.1200/jco.2011.29.15_suppl.2055
Lou, E., D. A. Reardon, K. Peters, A. Desjardins, J. E. Herndon, A. D. Coan, S. G. Turner, et al. “Upfront bevacizumab with temozolomide or with temozolomide and irinotecan for unresectable or multifocal glioblastoma.Journal of Clinical Oncology 29, no. 15_suppl (May 20, 2011): 2055–2055. https://doi.org/10.1200/jco.2011.29.15_suppl.2055.
Lou E, Reardon DA, Peters K, Desjardins A, Herndon JE, Coan AD, et al. Upfront bevacizumab with temozolomide or with temozolomide and irinotecan for unresectable or multifocal glioblastoma. Journal of Clinical Oncology. 2011 May 20;29(15_suppl):2055–2055.
Lou, E., et al. “Upfront bevacizumab with temozolomide or with temozolomide and irinotecan for unresectable or multifocal glioblastoma.Journal of Clinical Oncology, vol. 29, no. 15_suppl, American Society of Clinical Oncology (ASCO), May 2011, pp. 2055–2055. Crossref, doi:10.1200/jco.2011.29.15_suppl.2055.
Lou E, Reardon DA, Peters K, Desjardins A, Herndon JE, Coan AD, Turner SG, Sumrall AL, Bailey L, Friedman HS, Vredenburgh JJ. Upfront bevacizumab with temozolomide or with temozolomide and irinotecan for unresectable or multifocal glioblastoma. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2011 May 20;29(15_suppl):2055–2055.

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2011

Volume

29

Issue

15_suppl

Start / End Page

2055 / 2055

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences